R&R Comments - $24 Target
07:40 SUPG SuperGen: Oncology Inc�s Dacogen numbers reflect continued growth - Rodman & Renshaw (4.57 )
Rodman & Renshaw says Oncology Inc.'s numbers for August reflect an increase of ~100 patients in the number treated with Dacogen, which brings the total to ~700 currently. Firm says this reflects a 16% increase in patient number vs. July. In terms of market share, firm says Dacogen had claimed 16% of the MDS market in August, compared to 14% in July. Firm's current modeling assumptions indicate ~$43 mln in sales for Y06, significantly above the $25 mln rev est provided as guidance from MGI Pharma (MOGN). Since it is now clear that the number of patients on Dacogen has continued to grow, firm remains confident that additional expansion of the patient population will be seen throughout the remainder of the year, indicating that the Y06 rev est of $25 mln from MOGN appears conservative. In light of another strong month for Dacogen, firm retains their Market Outperform rating on SuperGen shares with a tgt price of $24 per share.